Research has shown that AGG interruption analysis can help us provide you and your patients who are found to be fragile X premutation carriers with a more refined reproductive risk. [1, 2]
A higher number of AGG interruptions is associated with a lower risk of expansion. By counting the number of AGG repeats present, we can help refine the risk of a woman having a child affected with fragile X syndrome. [1, 2]
Counsyl is excited to announce that we are now offering AGG interruption analysis for select fragile X orders. 
Graph adapted from: www.fragilexcarrier.com
Applicable to ~1 in 200 women tested:*
1. Patients identified with 55-90 CGG repeats for fragile X syndrome will automatically receive AGG interruption analysis via Asuragen. There will be no additional charge for this feature.
2. A preliminary Foresight™ Carrier Screen report will be issued within the normal two week turnaround time with Fragile X CGG repeat results and an final report will be issued within 3 weeks of the preliminary report with the results of the AGG interruption analysis.
3. AGG interruption analysis can not be performed on saliva samples. If a saliva sample returns with 55-90 CGG repeats, a secondary blood collection kit will be sent to your clinic in order to complete AGG analysis.
*Based on internal data
An updated informed consent form is necessary to cover this analysis. Log into counsyl.com/healthcare to access this updated form.
Note: AGG interruption analysis is not available for international orders
Questions? Contact firstname.lastname@example.org or reach out directly to your Counsyl representative.
March 17, 2021
NAVIGATING YOUR BREAST AND OVARIAN HEALTH IN THE (NEVER-ENDING) ERA OF COVID
It has been almost a year since most of us found ourselves in the completely unchartered territory of “sheltering in…Read more about NAVIGATING YOUR BREAST AND OVARIAN HEALTH IN THE (NEVER-ENDING) ERA OF COVID
February 25, 2021
I Am Glad to Know: The Importance of Carrier Screening Through the Voice of a Carrier
This Sunday, February 28th, is #RareDiseaseDay! To raise awareness and support for the rare disease community, Myriad Women’s Health partnered…Read more about I Am Glad to Know: The Importance of Carrier Screening Through the Voice of a Carrier
December 23, 2020
Myriad’s 7 Greatest Hits in 2020
Before we say goodbye to 2020, we’d like to thank and recognize our partners. Together, we ensure patients have access…Read more about Myriad’s 7 Greatest Hits in 2020